Stock Analysis

Solvar Full Year 2023 Earnings: Revenues Disappoint

ASX:SVR
Source: Shutterstock

Solvar (ASX:SVR) Full Year 2023 Results

Key Financial Results

  • Revenue: AU$209.3m (up 11% from FY 2022).
  • Net income: AU$47.6m (down 7.7% from FY 2022).
  • Profit margin: 23% (down from 28% in FY 2022). The decrease in margin was driven by higher expenses.
  • EPS: AU$0.23 (down from AU$0.24 in FY 2022).
earnings-and-revenue-growth
ASX:SVR Earnings and Revenue Growth August 19th 2023

All figures shown in the chart above are for the trailing 12 month (TTM) period

Solvar Revenues Disappoint

Revenue missed analyst estimates by 1.3%. Earnings per share (EPS) was mostly in line with analyst estimates.

Looking ahead, revenue is forecast to grow 7.3% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Consumer Finance industry in Australia.

Performance of the Australian Consumer Finance industry.

The company's shares are up 9.2% from a week ago.

Risk Analysis

We should say that we've discovered 4 warning signs for Solvar (3 are a bit concerning!) that you should be aware of before investing here.

Valuation is complex, but we're helping make it simple.

Find out whether Solvar is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.

View the Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.